Novo Nordisk A/S $NVO Shares Sold by Zevin Asset Management LLC

Zevin Asset Management LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 10.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,740 shares of the company’s stock after selling 8,951 shares during the quarter. Zevin Asset Management LLC’s holdings in Novo Nordisk A/S were worth $5,228,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of NVO. Jennison Associates LLC increased its stake in Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after buying an additional 63,341 shares during the period. Kingstone Capital Partners Texas LLC grew its stake in shares of Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after acquiring an additional 10,001,898 shares in the last quarter. Folketrygdfondet increased its position in shares of Novo Nordisk A/S by 6.9% during the first quarter. Folketrygdfondet now owns 9,521,912 shares of the company’s stock worth $661,202,000 after acquiring an additional 617,974 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Novo Nordisk A/S by 11.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company’s stock valued at $395,291,000 after acquiring an additional 576,900 shares in the last quarter. Finally, Sustainable Growth Advisers LP boosted its holdings in Novo Nordisk A/S by 3.8% in the first quarter. Sustainable Growth Advisers LP now owns 5,543,246 shares of the company’s stock valued at $384,923,000 after purchasing an additional 202,443 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NVO shares. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 16th. Hsbc Global Res upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, August 5th. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $55.00 target price (up previously from $50.00) on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Stock Down 1.0%

Shares of NYSE:NVO opened at $46.04 on Friday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $112.52. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm’s 50-day simple moving average is $55.54 and its 200-day simple moving average is $61.58. The company has a market cap of $205.56 billion, a price-to-earnings ratio of 12.66, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.